Skip to main content
2025
  • Selection for Cho-gyeok-cha (Super Gap) Startup 1,000+ Linked Support Program (Jan)
  • Establishment of a Corporate R&D Center within the College of Pharmacy, Seoul National University (Jan)
  • Beginning IIT Phase 1 clinical trial collaboration with MD Anderson Cancer Center (Sep)
  • KRW 500 million in Bridge funding (Dec)
2024
  • Korean patent application filed for PLM-103 (Jan)
  • Selection for the Cho-gyeok-cha(Super Gap) Startup 1,000 Support Program (Apr)
  • IND approval for PLM-102 from the MFDS (Korea) and the U.S. FDA (May)
2023
  • Completion of preclinical studies for PLM-102 (Jun)
  • Patent applications for PLM-102 filed in 9 countries (Dec)
2022
  • Selection as a Bio Core Facility partner by Asan Medical Center, Seoul (Jan)
  • Selection for Baby Unicorn 200 Fostering Program (May)
  • KRW 5.5 billion in Series A Bridge funding (Dec)
2021
  • Selection for the Innovation Startup Package Commercialization Program (Jan)
2020
  • Selection for the Big3 Startup R&D Package (Dec)
  • KRW 6.5 billion in Series A funding (Dec)
2019
  • PeLeMed founded (May)
  • Certificate of Venture business (Sep)
  • Moved into SEOUL BIOHUB (Nov)
  • PLM-102 Patent Application Filing (Dec)
  • Technology transfer of PLM-101 and PLM-102 from GIST (Dec)

2022

  • ASAN Medical Center Bio Core Facility Funding (Jan)
  • IP Voucher Funded by MSS* (March)
  • Bio Research Data Funding (April)
  • Selected Baby Unicorn 200 Funding (May)
  • Series A bridge Funding US$ 3mil. (May)
  • Initiated Non Clinical Trial for PLM-102 Candidate
  • Initiated Preparation for PLM-401 Phase I trial
* MSS: The Ministry of SMEs and Startup

2021

  • Established Internal Company R&D Lab (Jan)
  • Big3 Startup Package Commercialization Funding (Jan)
  • IP Voucher Funded by KISTA* (April)
  • Bio health Investment-Infra R&D Funding (July)
  • PLM-105 selected as NDDP* and Funded by KDDF* (July)
  • Licensed In PLM-401 (Dec)
  • PLM-401 Phase I IND approved (Dec)
* KISTA: Korea Intellectual property STrategy Agency
* NDDP: National Drug Development Project
* KDDF: Korea Drug Development Fund

2020

  • Moved into Poongjeon Bldg. (Nov)
  • Big3 Startup Package R&D Funding (Dec)
  • APEX anti tumor PK Advisory Service Funding (Dec)
  • Series A Funding US$ 5.5mil. (Dec)

2019

  • PeLeMed founded (May)
  • Certificate of Venture business (Sep)
  • Moved into SEOUL BIOHUB (Nov)

2022

  • ASAN Medical Center Bio Core Facility Funding (Jan)
  • IP Voucher Funded by MSS* (March)
  • Bio Research Data Funding (April)
  • Selected Baby Unicorn 200 Funding (May)
  • Series A bridge Funding US$ 3mil. (May)
  • Initiated Non Clinical Trial for PLM-102 Candidate
  • Initiated Preparation for PLM-401 Phase I trial
* MSS: The Ministry of SMEs and Startup

2021

  • Established Internal Company R&D Lab (Jan)
  • Big3 Startup Package Commercialization Funding (Jan)
  • IP Voucher Funded by KISTA* (April)
  • Bio health Investment-Infra R&D Funding (July)
  • PLM-105 selected as NDDP* and Funded by KDDF* (July)
  • Licensed In PLM-401 (Dec)
  • PLM-401 Phase I IND approved (Dec)
* KISTA: Korea Intellectual property STrategy Agency
* NDDP: National Drug Development Project
* KDDF: Korea Drug Development Fund

2020

  • Moved into Poongjeon Bldg. (Nov)
  • Big3 Startup Package R&D Funding (Dec)
  • APEX anti tumor PK Advisory Service Funding (Dec)
  • Series A Funding US$ 5.5mil. (Dec)

2019

  • PeLeMed founded (May)
  • Certificate of Venture business (Sep)
  • Moved into SEOUL BIOHUB (Nov)

2022

  • ASAN Medical Center Bio Core Facility Funding (Jan)
  • IP Voucher Funded by MSS* (March)
  • Bio Research Data Funding (April)
  • Selected Baby Unicorn 200 Funding (May)
  • Series A bridge Funding US$ 3mil. (May)
  • Initiated Non Clinical Trial for PLM-102 Candidate
  • Initiated Preparation for PLM-401 Phase I trial
* MSS: The Ministry of SMEs and Startup

2020

  • Moved into Poongjeon Bldg. (Nov)
  • Big3 Startup Package R&D Funding (Dec)
  • APEX anti tumor PK Advisory Service Funding (Dec)
  • Series A Funding US$ 5.5mil. (Dec)

2021

  • Established Internal Company R&D Lab (Jan)
  • Big3 Startup Package Commercialization Funding (Jan)
  • IP Voucher Funded by KISTA* (April)
  • Bio health Investment-Infra R&D Funding (July)
  • PLM-105 selected as NDDP* and Funded by KDDF* (July)
  • Licensed In PLM-401 (Dec)
  • PLM-401 Phase I IND approved (Dec)
* KISTA: Korea Intellectual property STrategy Agency * NDDP: National Drug Development Project * KDDF: Korea Drug Development Fund

2019

  • PeLeMed founded (May)
  • Certificate of Venture business (Sep)
  • Moved into SEOUL BIOHUB (Nov)